Myeloid Leukemia

Oncology·MeSH: Precursor Cell Lymphoblastic Leukemia-Lymphoma

Prevalence

5.0 / 100K

206 drugs in development·83 companies·2 clinical trials

Drug Pipeline by Phase

Approved(18)

Drug	Company
company's product candidate uproleselan	CRESCENT BIOPHARMA, INC. (CBIO)
daurismo	PFIZER INC (PFE)
hydroxyurea	AVEDRO INC (AVDR)
imatinib	Teva Pharmaceutical Industries Limited (TEVA)
imatinib	Mylan II B.V. (MYL)
imatinib	Amneal Pharmaceuticals, Inc. (AMRX)
imatinib	Aptinyx Inc. (APTX)
imatinib	SUNSET ISLAND GROUP (SUN)
imatinib	DR REDDYS LABORATORIES LTD (RDY)
imkeldi	CG Oncology, Inc. (CGON)
komzifti	Kura Oncology, Inc. (KURA)
nilotinib	Aptinyx Inc. (APTX)
nilotinib	Mersana Therapeutics, Inc. (MRSN)
nilotinib	DR REDDYS LABORATORIES LTD (RDY)
nypozi	GT Biopharma, Inc. (GTBP)
Revuforj	Syndax Pharmaceuticals Inc (SNDX)
rezlidhia	RIGEL PHARMACEUTICALS INC (RIGL)
venetoclax	DR REDDYS LABORATORIES LTD (RDY)

Phase 3(47)

Drug	Company
BGB-11417	BeOne Medicines Ltd. (ONC)
bosutinib	ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)
cellcept	ENANTA PHARMACEUTICALS INC (ENTA)
cellcept	Structure Therapeutics Inc. (GPCR)
cellcept	Filana Therapeutics Inc. (FLNA)
ceplene	IMMUNE PHARMACEUTICALS INC (IMNP)
Cladribine	Jazz Pharmaceuticals plc (JAZZ)
clifutinib	SUNSHINE BIOPHARMA INC. (SBFM)
CPX-351	Jazz Pharmaceuticals plc (JAZZ)
Cytarabine	Jazz Pharmaceuticals plc (JAZZ)
Cytarabine	Merus N.V. (MRUS)
Cytarabine + Daunorubicin + Gilteritinib	Merus N.V. (MRUS)
Cytarabine + Daunorubicin + Gilteritinib	Crinetics Pharmaceuticals, Inc. (CRNX)
Daunorubicin	Jazz Pharmaceuticals plc (JAZZ)
Daunorubicin	AbbVie Inc. (ABBV)
Daunorubicin Hydrochloride	Merus N.V. (MRUS)
Daunorubicin Hydrochloride	ENANTA PHARMACEUTICALS INC (ENTA)
galinpepimut-s	SELLAS Life Sciences Group, Inc. (SLS)
gilteritinib	GH Research PLC (GHRS)
Gilteritinib Fumarate	Assertio Holdings, Inc. (ASRT)
gm-csf	SELLAS Life Sciences Group, Inc. (SLS)
HiDAC	Merus N.V. (MRUS)
High intensity therapies	Structure Therapeutics Inc. (GPCR)
hmpl-306 regimen	HUTCHMED (China) Ltd (HMDCF)
Idarubicin	AbbVie Inc. (ABBV)
Intensive Chemotherapy Regimen	Syndax Pharmaceuticals Inc (SNDX)
JCAR017 + venetoclax	Merus N.V. (MRUS)
Liposome-encapsulated Daunorubicin-Cytarabine	Jazz Pharmaceuticals plc (JAZZ)
Liposome-encapsulated Daunorubicin-Cytarabine	Merus N.V. (MRUS)
Low intensity therapies	Structure Therapeutics Inc. (GPCR)
Low intensity therapies	Crinetics Pharmaceuticals, Inc. (CRNX)
nilotinib	GH Research PLC (GHRS)
pevonedistat	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
pevonedistat	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
ponatinib 30mg od	GH Research PLC (GHRS)
ponatinib 45mg od	GH Research PLC (GHRS)
Revumenib	UNITED THERAPEUTICS Corp (UTHR)
salvage chemotherapy regimen	HUTCHMED (China) Ltd (HMDCF)
salvage chemotherapy regimen	HUTCHMED (China) Limited (HCM)
Tacrolimus	Structure Therapeutics Inc. (GPCR)
Tacrolimus	Filana Therapeutics Inc. (FLNA)
Venetoclax	ENANTA PHARMACEUTICALS INC (ENTA)
Venetoclax	Crinetics Pharmaceuticals, Inc. (CRNX)
Venetoclax	Merus N.V. (MRUS)
Venetoclax	UNITED THERAPEUTICS Corp (UTHR)
Venetoclax 400	UNITED THERAPEUTICS Corp (UTHR)
Vyxeos	Jazz Pharmaceuticals plc (JAZZ)

Phase 2(54)

Drug	Company
ABBV-787	AbbVie Inc. (ABBV)
abl001/asciminib	Novartis AG (NVS)
acr-6840	Acrivon Therapeutics, Inc. (ACRV)
ALT-803	ImmunityBio, Inc. (IBRX)
Asciminib	Novartis AG (NVS)
bcr-abl tyrosine kinase inhibitor	GH Research PLC (GHRS)
BP1001	BIO-PATH HOLDINGS, INC. (BPTH)
Busulfan	Merus N.V. (MRUS)
Busulfan	Valneva SE (VALN)
Cytarabine	ENANTA PHARMACEUTICALS INC (ENTA)
daunorubicin	Merus N.V. (MRUS)
Daunorubicin	ENANTA PHARMACEUTICALS INC (ENTA)
daunorubicin or idarubicin	NOVARTIS AG (NVSEF)
daunorubicin or idarubicin	Novartis AG (NVS)
Enasidenib	Merus N.V. (MRUS)
Filgrastim	Merus N.V. (MRUS)
fludarabine	Novartis AG (NVS)
fludarabine	NOVARTIS AG (NVSEF)
Fludarabine	Valneva SE (VALN)
Fludarabine	Merus N.V. (MRUS)
Fludarabine Phosphate	Merus N.V. (MRUS)
G-CSF	ImmunityBio, Inc. (IBRX)
gemtuzumab ozogamicin	GH Research PLC (GHRS)
Gemtuzumab Ozogamicin	Merus N.V. (MRUS)
Gemtuzumab Ozogamicin	ENANTA PHARMACEUTICALS INC (ENTA)
Gilteritinib	Merus N.V. (MRUS)
imatinib	Novartis AG (NVS)
Inotuzumab ozogamicin	Merus N.V. (MRUS)
Luveltamab tazevibulin	SUTRO BIOPHARMA, INC. (STRO)
Melphalan	Valneva SE (VALN)
Melphalan	Merus N.V. (MRUS)
mitoxantrone	NOVARTIS AG (NVSEF)
mitoxantrone	Novartis AG (NVS)
mitoxantrone	GH Research PLC (GHRS)
Mitoxantrone	Jazz Pharmaceuticals plc (JAZZ)
mt-401	Marker Therapeutics, Inc. (MRKR)
mt-401-ots	Marker Therapeutics, Inc. (MRKR)
Mycophenolate mofetil	ImmunityBio, Inc. (IBRX)
nexi-001	NexImmune, Inc. (NEXI)
Olutasidenib	Merus N.V. (MRUS)
oxi4503	Oncotelic Therapeutics, Inc. (OTLC)
Pegfilgrastim	Merus N.V. (MRUS)
pivekimab sunirine	ImmunoGen, Inc. (IMGN)
Recombinant Granulocyte Colony-Stimulating Factor	Jazz Pharmaceuticals plc (JAZZ)
rtx-240	Rubius Therapeutics, Inc. (RUBY)
Tacrolimus	ImmunityBio, Inc. (IBRX)
tagraxofusp	STEMLINE THERAPEUTICS INC (STML)
tamibarotene	Syros Pharmaceuticals, Inc. (SYRS)
tcb008	TC BioPharm (Holdings) plc (TCBWF)
tern-501	Terns Pharmaceuticals, Inc. (TERN)
tern-701	Terns Pharmaceuticals, Inc. (TERN)
tern-801	Terns Pharmaceuticals, Inc. (TERN)
Venetoclax	Valneva SE (VALN)
Vincristine Sulfate Liposome	Merus N.V. (MRUS)

Phase 1(52)

Drug	Company
ACLX-002	Arcellx, Inc. (ACLX)
ADCLEC.syn1 CAR T cells	Merus N.V. (MRUS)
ADCLEC.syn1 CAR T cells	Filana Therapeutics Inc. (FLNA)
Alvocidib	AbbVie Inc. (ABBV)
AMG 176	AbbVie Inc. (ABBV)
astx727	CG Oncology, Inc. (CGON)
ASTX727	Syndax Pharmaceuticals Inc (SNDX)
BMF-500	Biomea Fusion, Inc. (BMEA)
CB-012	Caribou Biosciences, Inc. (CRBU)
cb-5339	CASI Pharmaceuticals, Inc (DE) (CASI)
CD371-specific/YSNVz/I-18 CAR T cells	Merus N.V. (MRUS)
Chemotherapy Regimen	Syndax Pharmaceuticals Inc (SNDX)
Conditioning chemotherapy	Filana Therapeutics Inc. (FLNA)
Cytarabine	Structure Therapeutics Inc. (GPCR)
Cytarabine	Syndax Pharmaceuticals Inc (SNDX)
Cytarabine	Accustem Sciences Inc. (ACUT)
elvn-001	Enliven Therapeutics, Inc. (ELVN)
Etoposide Phosphate	Accustem Sciences Inc. (ACUT)
Fludarabine	AbbVie Inc. (ABBV)
Gemtuzumab Ozogamicin	Jazz Pharmaceuticals plc (JAZZ)
Gilteritinib	AbbVie Inc. (ABBV)
Gilteritinib	Jazz Pharmaceuticals plc (JAZZ)
Granulocyte Colony-Stimulating Factor	AbbVie Inc. (ABBV)
HiDAC	Syndax Pharmaceuticals Inc (SNDX)
Iadademstat	Merus N.V. (MRUS)
Idarubicin	Structure Therapeutics Inc. (GPCR)
Imetelstat	Assertio Holdings, Inc. (ASRT)
KT-253	Kymera Therapeutics, Inc. (KYMR)
Mitoxantrone Hydrochloride	Accustem Sciences Inc. (ACUT)
Navtemadlin	Merus N.V. (MRUS)
nc525	NextCure, Inc. (NXTC)
Pitavastatin	UNITED THERAPEUTICS Corp (UTHR)
Pivekimab Sunirine	Structure Therapeutics Inc. (GPCR)
Pivekimab Sunirine	AbbVie Inc. (ABBV)
quizartinib	Kura Oncology, Inc. (KURA)
Revumenib	AbbVie Inc. (ABBV)
Revumenib	Merus N.V. (MRUS)
Revumenib	Syndax Pharmaceuticals Inc (SNDX)
sgr-2921	Schrodinger, Inc. (SDGR)
siremadlin	Novartis AG (NVS)
sl-172154	Shattuck Labs, Inc. (STTK)
SNDX-5613	Syndax Pharmaceuticals Inc (SNDX)
SNDX-5613	Merus N.V. (MRUS)
Tazemetostat	Merus N.V. (MRUS)
Venetoclax	Actinium Pharmaceuticals, Inc. (ATNM)
Venetoclax	Syndax Pharmaceuticals Inc (SNDX)
voruciclib	Lite Strategy, Inc. (LITS)
vyxeos	GH Research PLC (GHRS)
Vyxeos liposomal	Jazz Pharmaceuticals plc (JAZZ)
ze 50-0134	Rani Therapeutics Holdings, Inc. (RANI)
ze50-0134	Rani Therapeutics Holdings, Inc. (RANI)
ZN-d5	Zentalis Pharmaceuticals, Inc. (ZNTL)

Preclinical(12)

Drug	Company
ACLX-004	Arcellx, Inc. (ACLX)
BCR-ABL TKI	Theseus Pharmaceuticals, Inc. (THRX)
cd38-gear-nk	COEPTIS THERAPEUTICS INC. (NDYN)
CD38-GEAR-NK	Coeptis Therapeutics Holdings Inc. (COEP)
gb3226	Damora Therapeutics, Inc. (DMRA)
oncotox-aml	OMEROS CORP (OMER)
prime edited scip	Prime Medicine, Inc. (PRME)
rasp-101	ACTAVIA LIFE SCIENCES, INC. (RASP)
rasp-201	ACTAVIA LIFE SCIENCES, INC. (RASP)
rasp-301	ACTAVIA LIFE SCIENCES, INC. (RASP)
tp-2846	TETRAPHASE PHARMACEUTICALS INC (TTPH)
tp-2846	LA JOLLA PHARMACEUTICAL CO (LJPC)

Unknown(1)

Drug	Company
BST-236	Ayala Pharmaceuticals, Inc. (ADXS)

Clinical(1)

Drug	Company
ast-vac1	ASTERIAS BIOTHERAPEUTICS, INC. (AST)

Phase 1/Phase 2(12)

Drug	Company
asciminib adult formulation group	Novartis AG (NVS)
asciminib pediatric formulation group	Novartis AG (NVS)
CLN-049	Cullinan Therapeutics, Inc. (CGEM)
cobicistat	Syndax Pharmaceuticals Inc (SNDX)
debio 1562m	HWH International Inc. (HWH)
ft-2102	Forma Therapeutics Holdings, Inc. (FMTX)
nkx101	Nkarta, Inc. (NKTX)
ponatinib	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
ponatinib	Incyte Corp. (INCY)
Posaconazole	BeOne Medicines Ltd. (ONC)
sar443579	Sanofi (SNY)
UCART123v1.2	Cellectis S.A. (CLLS)

Phase 2/Phase 3(1)

Drug	Company
Actimab-A	Actinium Pharmaceuticals, Inc. (ATNM)

Phase 4(8)

Drug	Company
asciminib	Novartis AG (NVS)
bms-986497	BRISTOL MYERS SQUIBB CO (BMY)
bosutinib	Novartis AG (NVS)
cyp1a2	RIGEL PHARMACEUTICALS INC (RIGL)
nilotinib	Novartis AG (NVS)
nilotinib	Novartis AG (NVS)
ponatinib	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
Venetoclax	AbbVie Inc. (ABBV)

Compare drugs

company's product candidate uproleselan vs daurismo company's product candidate uproleselan vs hydroxyurea company's product candidate uproleselan vs imatinib

Frequently asked questions

How many drugs are in development for Myeloid Leukemia?

BioSniper tracks 206 drugs in development for Myeloid Leukemia across 83 companies.

How many clinical trials target Myeloid Leukemia?

There are 2 clinical trials targeting Myeloid Leukemia tracked by BioSniper.

What is the prevalence of Myeloid Leukemia?

The estimated prevalence of Myeloid Leukemia is approximately 5.0 per 100,000 population.

Deep-dive into Myeloid Leukemia

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis